In conclusion, our data indicate that BMP8B enhances different pathophysiological steps of NAFLD progression and suggest BMP8B as a promising prognostic marker and therapeutic target for NAFLD and, potentially, also for other chronic liver diseases. The gene discussed is BMP8B; the disease is metabolic dysfunction-associated steatotic liver disease.